Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression.
DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression. Tanyi, J., Dorigo, O., Oza, A. M., Strauss, J., Pejovic, T., Ghamande, S. A., Ghatage, P., Villella, J. A., Fiset, S., MacDonald, L., Hrytsenko, O., Stanford, M., Newton, R. C., Leopold, L., Rosu, G. AMER SOC CLINICAL ONCOLOGY. 2019View details for DOI 10.1200/JCO.2019.37.15_suppl.5576
View details for Web of Science ID 000487345805567